Evidence map›Paper›PMID 37133922›Full record

ArticleJMIR diabetes2023

Fitterfly Diabetes CGM Digital Therapeutics Program for Glycemic Control and Weight Management in People With Type 2 Diabetes Mellitus: Real-world Effectiveness Evaluation.

Shilpa Joshi, Ritika Verma, Tejal Lathia, Chitra Selvan, Snehal Tanna, Amit Saraf, Mangesh Tiwaskar, Alok Modi, Sanjay Kalra, Vasudevarao K and 4 more

Open access · goldAbstract read
In one paragraph

Article in JMIR diabetes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Adoption of Digital Therapeutics in Europe.Therapeutics and clinical risk management · 2024
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Shilpa Joshi *Department of Metabolic Nutrition, Fitterfly HealthTech Pvt Ltd, Navi Mumbai, India.ORCID https://orcid.org/0000-0003-3445-9357
Ritika Verma *Department of Scientific writing and Research, Fitterfly HealthTech Pvt Ltd, Navi Mumbai, India.ORCID https://orcid.org/0000-0001-8113-8703
Tejal LathiaDepartment of Endocrinology and Diabetology, Apollo Hospitals, Navi Mumbai, India.ORCID https://orcid.org/0000-0002-4481-6197
Chitra SelvanDepartment of Endocrinology and Diabetology, MS Ramaiah Memorial Hospital, Bangalore, India.ORCID https://orcid.org/0000-0001-6750-8982
Snehal TannaDepartment of Internal Medicine, Jupiter Hospital, Thane, India.ORCID https://orcid.org/0000-0001-6082-8510
Amit SarafDepartment of Internal Medicine, Jupiter Hospital, Thane, India.ORCID https://orcid.org/0000-0002-6879-9459
Mangesh TiwaskarDepartment of Diabetology, Shilpa Medical Research Center, Mumbai, India.ORCID https://orcid.org/0000-0003-4024-0095
Alok ModiDepartment of General Medicine, Kevalya Hospital, Thane, India.ORCID https://orcid.org/0009-0003-9524-2562
Sanjay KalraDepartment of Endocrinology and Diabetology, Bharti Research Institute of Diabetes and Endocrinology, Haryana, India.ORCID https://orcid.org/0000-0003-1308-121X
Vasudevarao KDepartment of Endocrinology and Diabetology, Hridayam Diabetes World, Thane, India.ORCID https://orcid.org/0009-0001-3693-9090
Manoj ChitaleDepartment of General Medicine, Shree Clinic, Nashik, India.ORCID https://orcid.org/0009-0007-8821-356X
Forum MaldeDepartment of Metabolic Nutrition, Fitterfly HealthTech Pvt Ltd, Navi Mumbai, India.ORCID https://orcid.org/0009-0000-3255-4620
Mohammed Abdul KhaderDepartment of Scientific writing and Research, Fitterfly HealthTech Pvt Ltd, Navi Mumbai, India.ORCID https://orcid.org/0000-0002-1443-2635
Arbinder Kumar SingalOffice of Chief Executive Officer, Fitterfly HealthTech Pvt Ltd, Navi Mumbai, India.ORCID https://orcid.org/0000-0002-7738-4327
Diabetes Foundation · INApollo Hospitals · INBharti Hospital · INM S Ramaiah Memorial Hospital · INShilpa (India) · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDigital therapeutic platforms facilitate health care through patient-centered strategies based on multidisciplinary teams and shared decision-making. Such platforms can be used for developing a dynamic model of diabetes care delivery, which can help in improving glycemic control by promoting long-term behavior changes in people with diabetes.

objectiveThis study aims to evaluate the real-world effectiveness of the Fitterfly Diabetes CGM digital therapeutics program for improving glycemic control in people with type 2 diabetes mellitus (T2DM) after the completion of 90 days in the program.

methodsWe analyzed deidentified data of 109 participants in the Fitterfly Diabetes CGM program. This program was delivered through the Fitterfly mobile app coupled with continuous glucose monitoring (CGM) technology. This program consists of 3 phases: the first phase is observation, wherein the patient's CGM readings are observed for 7 days (week 1); the second phase is the intervention; and the third phase aims at sustaining the lifestyle modification introduced during the second phase. The primary outcome of our study was the change in the participants' hemoglobin A

resultsAt the end of the 90 days of the program, the mean HbA

conclusionsOur study shows that participants in the Fitterfly Diabetes CGM program showed a significant improvement in their glycemic control and reduction in weight and BMI. They also showed a high level of engagement with the program. Weight reduction was significantly associated with higher participant engagement with the program. Thus, this digital therapeutic program can be considered as an effective tool for improving glycemic control in people with T2DM.

Indexed as

applicationcontinuous glucose monitoringdecision-makingdiabetesdigital therapeuticseffectivenessengagementglucoseglycemicglycemic controlmobile applicationmodelmonitoringtype 2 diabetes

Identifiers

PMID37133922
PMCPMC10193208
OpenAlexW4323529973

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.